News
Daiichi Sankyo and AstraZeneca’s Enhertu delivers promising trial results
Daiichi Sankyo and AstraZeneca’s breast cancer treatment, trastuzumab deruxtecan – also known as Enhertu – has been evaluated in the DESTINY-Breast04 study.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Daiichi Sankyo and AstraZeneca’s breast cancer treatment, trastuzumab deruxtecan – also known as Enhertu – has been evaluated in the DESTINY-Breast04 study.